Probiotic chocolate, Albendazole, Lactobacillus acidophilus, Pediatric drug delivery, Taste masking, Patient compliance

Helminth infections are among the most prevalent parasitic diseases worldwide and represent a major public health concern, particularly in developing countries with inadequate sanitation and hygiene. These infections are caused by parasitic worms such as roundworms, hookworms, whipworms, and tapeworms that inhabit the gastrointestinal tract. Children are especially vulnerable due to increased exposure to contaminated environments, and such infections can lead to malnutrition, anemia, abdominal discomfort, diarrhea, and impaired physical and cognitive development.

Albendazole is a widely used broad-spectrum anthelmintic drug belonging to the benzimidazole class. It acts by inhibiting microtubule formation in parasites, thereby disrupting glucose uptake and leading to parasite death. However, conventional dosage forms such as tablets and suspensions often result in poor patient compliance in pediatric populations due to unpleasant taste and difficulty in swallowing.

CHOCOLATE AS A DRUG DELIVERY SYSTEM

Chocolate has emerged as a novel and promising drug delivery system due to its unique physicochemical, organoleptic, and technological properties. It acts as an anhydrous carrier matrix, enhancing drug stability by preventing hydrolytic degradation. The lipid-rich composition of chocolate, primarily cocoa butter, provides a protective environment for active pharmaceutical ingredients.

Chocolate effectively masks the bitter taste of drugs, thereby improving palatability and patient compliance, particularly in pediatric patients. Its smooth texture and ability to melt at body temperature facilitate ease of administration without the need for water.

From a formulation perspective, chocolate allows the incorporation of both hydrophilic and lipophilic drugs and can also accommodate functional ingredients such as probiotics. However, challenges such as achieving uniform drug distribution, maintaining temperature control during processing, and preserving probiotic viability must be carefully addressed during formulation development.

Probiotics are beneficial microorganisms that help maintain intestinal microflora and improve gastrointestinal health. Lactobacillus acidophilus is one of the most widely used probiotic strains due to its ability to survive in acidic environments and support digestive health. The incorporation of probiotics along with anthelmintic therapy may help restore intestinal microbial balance disrupted during parasitic infections.

RESEARCH GAP

Although chocolate-based drug delivery systems and probiotic therapies have been studied individually, there is limited research on integrating both into a single dosage form. Parasitic infections and their treatment can disrupt intestinal microflora. Therefore, combining an anthelmintic drug with probiotics in a chocolate-based formulation represents a novel and promising approach to simultaneously treat infections and restore gut health.

AIM

To formulate and evaluate a probiotic medicated chocolate containing Albendazole and Lactobacillus acidophilus for improved pediatric drug delivery and gastrointestinal health.

OBJECTIVES

1.    To develop a palatable pediatric-friendly chocolate formulation.

2.    To incorporate Albendazole as an effective anthelmintic agent.

3.    To include Lactobacillus acidophilus for probiotic benefits.

4.    To evaluate physicochemical properties such as appearance, thickness, weight variation, and texture.

5.    To determine drug content uniformity of the prepared formulation.

6.    To study the in-vitro drug release profile of Albendazole.

7.    To assess stability under suitable storage conditions.

NEED  OF THE STUDY

Helminth infections are common in developing countries and are commonly treated with anthelmintic drugs such as Albendazole. However, conventional dosage forms like tablets and suspensions often lead to poor patient compliance, especially in children, due to unpleasant taste and difficulty in swallowing. Chocolate-based drug delivery systems provide an effective approach for taste masking and improved acceptability, while probiotics such as Lactobacillus acidophilus help maintain gut microbiota balance and support gastrointestinal health. Therefore, this formulation represents an innovative approach to combine therapeutic treatment with probiotic supplementation in a convenient and patient-friendly dosage form.

LITERATURE REVIEW

Aulton¹ reported that the selection of an appropriate dosage form significantly influences drug stability and patient compliance. He emphasized that novel drug delivery systems, such as chocolate-based formulations, can improve palatability and patient acceptability.

Allen² stated that lipid-based drug delivery systems enhance the bioavailability of poorly water-soluble drugs and are particularly beneficial for drugs such as Albendazole.

Shah³ reported that probiotic cultures such as Lactobacillus acidophilus provide significant health benefits, including improved gut health and immune function.

Ranadheera et al.⁴ demonstrated that the efficacy of probiotics depends on the type of food carrier used and emphasized that fat-rich matrices improve probiotic survival and stability.

Beckett⁵ described chocolate as a suitable carrier for bioactive compounds due to its physicochemical stability and excellent taste-masking properties.

Patel and Velikov⁶ reported that colloidal delivery systems in food enhance the stability and controlled release of active ingredients.

Tripathi⁷ stated that Albendazole has poor aqueous solubility, which limits its bioavailability, and suggested that lipid-based formulations can improve its therapeutic effectiveness.

MATERIAL AND METHOD

DRUG DESCRIPTION:

Albendazole:

Introduction:

Albendazole is a widely used anti-parasitic medicine. It is effective against many intestinal worms and tissue parasites like roundworms, hookworms, and tapeworms. It is also used in public health programs to control worm infections

Mechanism of Action:

Albendazole works by damaging the internal structure of parasites. It stops them from

absorbing glucose (energy source), which leads to energy loss and eventually causes their death. It also affects their growth and reproduction.

Adverse effect:

•      Nausea , vomiting and abdominal pain.

•      Diarrhea ,headache and dizziness

•      Elevated liver enzymes (liver irritation)

•      Temporary hair loss (reversible)

•      Allergic reactions (rash, itching)

Structure:

FIG NO.1

IUPAC Name: Methyl 5-(propylsulfanyl)-1H-benzimidazol-2-ylcarbamate Molecular Formula:C₁₂H₁₅N₃O₂S

Molecular Weight:265.33 g/mol Structural features:

•      Benzimidazole ring: Core structure responsible for anti-parasitic activity

•      Carbamate group (-OCOOCH₃): Important for drug binding and activity

•      Propylthio side chain (-S–C₃H₇): Increases lipophilicity and enhances absorption

•      Heterocyclic compound: Contains nitrogen atoms in the ring

•      Poor water solubility: Helps in localized action in intestine

•      Metabolized to active form: Converted in liver to albendazole sulfoxide (active metabolite)

Appearance of Albendazole:

•           White to off-white crystalline powder

•           Odorless or nearly odorless

•           Slightly bitter taste

•           Poorly soluble in water

•           More soluble in organic solvents like alcohol

Lactobacillus Acidophilus

Introduction:

Lactobacillus acidophilus is a beneficial bacterium found in the human gut, mouth, and vagina. It is a probiotic that helps maintain a healthy balance of microorganisms in the body. It is commonly present in yogurt and fermented foods.

Mechanism of Action:

Lactobacillus acidophilus works by converting sugars into lactic acid, which makes the intestine slightly acidic and prevents harmful bacteria from growing, it also competes with harmful germs for space and food, produces natural substances that kill bad bacteria, helps maintain a healthy balance of good bacteria in the gut, and supports the immune system to keep the body protected.

Structure

 

         

 

FIG NO.2

RESULT

The probiotic medicated chocolate containing Albendazole and Lactobacillus acidophilus showed satisfactory organoleptic properties with smooth texture, uniform appearance, and effective taste masking.

The average weight was 5.02 ± 0.9 g, hardness was 3.5 ± 0.4 kg/cm², friability was 0.42%, and thickness was 5.1 ± 0.2 mm. Drug content was found to be 98.7 ± 1.1%.

The formulation exhibited a disintegration time of 5.8 ± 0.6 min and released 90.2 ± 2.3% of the drug within 30 min. Probiotic viability was maintained at 1.2 × 10⁶ CFU/g.

Stability studies showed no significant changes in physical characteristics or drug content, with no evidence of fat or sugar bloom.

DISCUSSION

The present study successfully developed a probiotic medicated chocolate containing Albendazole and Lactobacillus acidophilus, designed to improve pediatric compliance and therapeutic efficacy. The chocolate-based delivery system provided effective taste masking and a stable lipid matrix, supporting uniform drug distribution and formulation stability.

Physicochemical parameters such as weight variation, hardness, friability, and thickness were within acceptable limits, confirming uniformity and mechanical strength. The in-vitro drug release showed efficient release of Albendazole, likely due to the melting property of chocolate at body temperature, which enhances drug availability, especially for poorly soluble drugs.

The probiotic component maintained good viability when incorporated below 40°C, indicating that the formulation process preserved microbial stability. This supports the role of lipid-based matrices in protecting probiotics during processing and storage.

The combination of Albendazole with Lactobacillus acidophilus offers a dual benefit by treating parasitic infections while supporting gut microbiota. Stability studies showed no significant changes, confirming the suitability of chocolate as a delivery system.

Overall, the formulation demonstrates potential as a palatable and effective alternative to conventional dosage forms. Further in-vivo studies are recommended to confirm clinical efficacy.

CONCLUSION

The present study successfully developed and evaluated a probiotic medicated chocolate formulation containing albendazole and Lactobacillus acidophilus. The formulation exhibited satisfactory physicochemical properties, including uniform weight, adequate mechanical strength, and acceptable organoleptic characteristics. The in vitro drug release profile indicated efficient drug release within the specified time, while the probiotic component maintained satisfactory viability under optimized conditions.

The combination of albendazole with a probiotic in a chocolate-based delivery system may improve patient compliance, particularly in pediatric populations, by providing effective taste masking and ease of administration. Overall, the developed formulation represents a promising alternative to conventional dosage forms and indicates potential for improved therapeutic performance.

However, further in vivo studies and clinical evaluations are recommended to confirm the efficacy, safety, and long-term stability of the formulation

REFERENCES

1. Aulton ME, Taylor KMG. Aulton’s pharmaceutics: the design and manufacture of medicines. 5th ed. London: Elsevier; 2018.
2. Allen LV. Pharmaceutical dosage forms and drug delivery systems. 11th ed. Philadelphia: Wolters Kluwer; 2020.
3. Shah NP. Functional cultures and health benefits. Int Dairy J. 2007;17(11):1262–1277.
4. Ranadheera RDCS, Baines SK, Adams MC. Importance of food in probiotic efficacy. Food Res Int. 2010;43(1):1–7.
5. Beckett ST. Industrial chocolate manufacture and use. 4th ed. Oxford: Wiley-Blackwell; 2009.
6. Patel AR, Velikov KP. Colloidal delivery systems in foods: a general comparison with oral drug delivery. Curr Opin Colloid Interface Sci. 2011;16(6):434–441.
7. Tripathi KD. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
8. Patil SS, Shinde GV, More HN. Preparation and evaluation of chocolate drug delivery system of albendazole. Res J Pharm Technol. 2016;9(11):1993–1996.
9. Ingale AH, Londhe RC, Padwal PN, Meshram MB. Formulation and evaluation of albendazole tablets drug delivery systems. World J Biol Pharm Health Sci. 2025;24(2):43–48.
10. Kalva S, Nandikonda T, Neha A. Formulation and evaluation of probiotic chocolate. Int J Pharm Sci Res. 2024;15(2):534–542.
11. Vasani C, Shah K. Preparation and evaluation of chocolate drug delivery system of albendazole. Res J Pharm Technol. 2016;9(11):1757–1762.
12. Jafarei P, Ebrahimi MT. Lactobacillus acidophilus: cell structure and application. Afr J Microbiol Res. 2011;5(24):4033–4042.
13. Palanichamy S, Anusha V, Solairaj P, Parasakthi N, Rajadhas G, ThangaThirupathi A. Formulation and evaluation of albendazole fast dissolving tablets. Res J Pharm Technol. 2011;4(11):1717–1720.
14. Khan MA, Iqbal Z, Ahmad L. Formulation and evaluation of chocolate containing albendazole and ivermectin. World J Pharm Res. 2023;12(9):2825–2832.
15. Patel D, Mehta K. Formulation and evaluation of anthelmintic herbal chocolate for pediatric use. EPRA Int J Res Dev. 2025;10(6):1–5.
16. Verma S, Gupta A. Formulation development and evaluation of medicated chocolate of albendazole. World J Pharm Res. 2022;11(5):1900–1908.
17. Allen LV. Medicated lozenges and confectionery. In: Allen LV. The art, science, and technology of pharmaceutical compounding. Washington, DC: American Pharmacists Association; 2016.
18. Patel H, et al. Medicated chocolate: a novel approach for drug delivery. Int J Pharm Sci. 2021;12(4):112–118.
19. Kumar R, et al. Development and evaluation of pediatric-friendly oral drug delivery systems. J Drug Deliv Ther. 2023;1